A Clinical Study Evaluating the Safety and Efficacy of Universal CD19-Targeted CAR-T (UWD-CD19) Therapy for Refractory and Relapsed B-Cell Tumors
Latest Information Update: 05 Nov 2024
Price :
$35 *
At a glance
- Drugs REVO UWD 19 (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Wondercel Therapeutics
- 04 Nov 2024 New trial record